Cancer's next decade
After a decade of patient breakthroughs leveraging technologies like immunotherapy, ADCs and targeted therapies, cancer R&D is staring down its next era. Our expert panel will look at how the R&D landscape has shifted, new attempts to go after cancer's “undruggable” targets and how the field is thinking about where the goalposts are in what remains a crowded space.
Senior Vice President - Global Head of Oncology and Hematology Product Development
Genentech and Roche
Chief Scientific Officer, Therapeutic Innovation
Cancer Research Horizons